Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3967/bes2024.047 | DOI Listing |
Publication Analysis
Top Keywords
lecanemab unveiled
4
unveiled exploring
4
exploring alzheimer's
4
alzheimer's treatment
4
treatment advancements
4
advancements assessing
4
assessing strengths
4
strengths limitations
4
limitations therapeutic
4
therapeutic landscape
4
Similar Publications
Cathepsin B modulates microglial migration and phagocytosis of amyloid β in Alzheimer's disease through PI3K-Akt signaling.
Neuropsychopharmacology
September 2024
Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China.
Article Synopsis
- The FDA approved lecanemab, an anti-amyloid β monoclonal antibody, to treat early-stage Alzheimer's disease, highlighting the significance of Aβ clearance in therapy.
- Research focused on cathepsin B (CatB), a protein that appears crucial for microglia to effectively clear Aβ from the brain, which is essential for maintaining cognitive function.
- Findings show that lack of CatB worsens cognitive decline in mice and that increased Aβ promotes CatB expression in microglia, hinting at a link between CatB activity and inflammation as well as Aβ clearance mechanisms.
Lecanemab Unveiled: Exploring Alzheimer's Treatment Advancements, Assessing Strengths, Limitations, and Its Therapeutic Landscape Position.
Biomed Environ Sci
April 2024
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!